Virginia Commonwealth University

VCU Massey Cancer Center

New technology could detect liver cancer from a simple blood sample

New technology from ApoCell, Inc. that can detect liver cancer cells circulating in a patient’s bloodstream may remove the need for potentially dangerous liver biopsies, be used as a screening tool and, ultimately, speed up drug development, according to a pilot study presented this week by Virginia Commonwealth University (VCU) Massey Cancer Center researcher Andrew Poklepovic, M.D., at the AACR Annual Meeting 2012 in Chicago, IL.

Continue reading →

New compound discovered that rapidly kills liver cancer

Scientists have identified a new compound that rapidly kills hepatocellular carcinoma (HCC) cells, the most common form of liver cancer and fifth most common cancer worldwide, while sparing healthy tissue. The compound, Factor Qunolinone Inhibitor 1 (FQI1), works by inhibiting an oncogene originally discovered by a team of researchers led by Devanand Sarkar, M.B.B.S., Ph.D., Harrison Scholar at Virginia Commonwealth University (VCU) Massey Cancer Center, Blick Scholar and assistant professor in the Department of Human and Molecular Genetics and member of the VCU Institute of Molecular Medicine at VCU School of Medicine.

Continue reading →

Study finds patients receive half of recommended preventive health services at annual check-ups

More than 20 percent of U.S. adults receive periodic health examinations (PHE) each year, yet new research shows that patients who have an annual routine visit to their doctor may not receive recommended preventive screening tests and counseling services that could benefit their health. Recently published in the American Journal of Preventive Medicine, a study performed by a team of researchers led by Jennifer Elston Lafata, Ph.D., co-leader of the Cancer Prevention and Control program at Virginia Commonwealth University (VCU) Massey Cancer Center and professor of Social and Behavioral Health at VCU, found that 46 percent of eligible and due services were missed during PHEs.

Continue reading →

Researchers uncover new mechanism in multiple myeloma cells

Researchers at Virginia Commonwealth University Massey Cancer Center have discovered a mechanism in multiple myeloma cells that plays a critical role in the cells’ ability to resist treatments involving a class of drugs known as histone deacetylase inhibitors (HDACIs). The findings could lead to more effective treatments for multiple myeloma, leukemia and other malignant blood disorders.

Continue reading →

Lab research suggests clinical trial may be especially effective against rare mantle cell lymphoma

A multi-institutional Phase I clinical trial testing the effects of a new combination of chemotherapies on rare forms of lymphoma is poised to begin at Virginia Commonwealth University Massey Cancer Center. As the trial prepares to open, new laboratory research from Massey scientists suggests that the novel therapy may warrant particular attention in patients with mantle cell lymphoma (MCL), a relatively rare form of non-Hodgkin’s lymphoma.

Continue reading →